Table 4.
Summary of RFA studies in metastatic disease.
| Author | Primary tumor | Number of patients | Median followup | Outcomes | Most common toxicity |
|---|---|---|---|---|---|
| Yamakado et al. [42] | Colorectal | 71 | 19 (mean) | 3 yr OS: 46% Intrapulmonary recurrence: 47% |
Pneumothorax (47%) |
| Nakamura et al. [43] | Sarcoma | 20 | 18 mo. | 1 yr OS: 88% 3 yr OS: 29% Incomplete ablation: 45% |
Pneumothorax (65%) |
| Palussière et al. [44] | Sarcoma | 29 | 50 mo. | 1 yr OS: 92.2% 2 yr OS: 65.2% Incomplete ablation: 10% |
Pneumothorax (67.8%) |
| Yan et al. [45] | Colorectal | 55 | 24 mo. | 1 yr OS: 85% 2 yr OS: 64% PFS: 15 mo. |
Pneumothorax (29%) |
| King et al. [46] | Colorectal | 19 | 24.3 mo. | 1 yr LC: 90% | Pneumothorax (52%) |